Project Research Center for Nosocomial Infectious Diseases, Hiroshima University, Minami-ku, Hiroshima City, Hiroshima, Japan.
J Clin Microbiol. 2013 Aug;51(8):2735-8. doi: 10.1128/JCM.02649-12. Epub 2013 May 29.
Klebsiella pneumoniae showing high resistance to all β-lactams except imipenem, designated as ISMRK (imipenem-susceptible meropenem-resistant Klebsiella) is emerging in Japan. The carbapenem resistance of ISMRK cannot be screened by the Vitek and the RAISUS rapid automated susceptibility test systems, which may lead to inappropriate antimicrobial therapy, resulting in compromised patient outcomes.
产碳青霉烯酶肺炎克雷伯菌(Klebsiella pneumoniae)除亚胺培南(imipenem)外,对所有β-内酰胺类抗菌药物均高度耐药,被命名为 ISMRK(亚胺培南敏感美罗培南耐药肺炎克雷伯菌),在日本不断出现。Vitek 和 RAISUS 快速自动化药敏检测系统无法筛选出 ISMRK 的碳青霉烯酶耐药性,这可能导致抗菌药物治疗不当,从而影响患者的治疗效果。